WO2006000992A1 - Method and compositions useful for preventing and/or treating sensitive and/or dry skin - Google Patents
Method and compositions useful for preventing and/or treating sensitive and/or dry skin Download PDFInfo
- Publication number
- WO2006000992A1 WO2006000992A1 PCT/IB2005/052049 IB2005052049W WO2006000992A1 WO 2006000992 A1 WO2006000992 A1 WO 2006000992A1 IB 2005052049 W IB2005052049 W IB 2005052049W WO 2006000992 A1 WO2006000992 A1 WO 2006000992A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganism
- lactobacillus
- bifidobacterium
- composition
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to a method of cosmetic treatment and to a composition, in particular a cosmetic and/or dermatological composition, intended more particularly for preventing and/or treating skin described as sensitive and/or dry skin.
- sensitive skin is defined by , a specific reactivity of the skin.
- this reactivity is not the result of an immunological process, i.e. it does not occur only in skin that is already sensitized, in response to the presence of an allergen. Its mechanism is said to be aspecific.
- This skin reactivity generally results in the manifestation of signs of discomfort in response to the subject coming into contact with a triggering element that may have various origins. It may involve the application of a cosmetic product at the surface of the sensitive skin, food intake, or exposure to abrupt temperature variations, to atmospheric pollution and/or to ultraviolet or infrared rays. Associated factors such as age and the type of skin also exist. Thus, sensitive skin is more common in the case of dry or oily skin than in the case of normal skin.
- dysaesthetic sensations is intended to mean more or less painful sensations experienced in a region of skin, such as stinging, tingling, itching or pruritus, burning, heating, discomfort, tautness, etc.
- These subjective signs most commonly exist in the absence of visible chemical signs such as redness and desquamations. At this time, it is known that these skin irritation and intolerance reactions are in particular associated with a release of neuropeptides by the nerve endings in the epidermis and the dermis.
- EP 110 550 proposes using bacterial agents, in particular of the probiotic type, for stabilizing and/or regulating the skin ecoflora. These compounds are described therein as being effective for preventing the adhesion of pathogenic flora to the skin.
- these microorganisms in particular probiotic microorganisms, can prove to be effective, in particular in adults, for treating sensitive skin in particular associated with dry skin, with the proviso that they are combined with an effective amount of at least one divalent inorganic cation.
- the present invention relates to a method of cosmetic treatment for preventing and/or treating sensitive and/or dry skin, comprising the oral administration of at least an effective amount of at least one microorganism, in particular probiotic microorganism, and/or a fraction thereof and/or a metabolite thereof, in combination with an effective amount of at least one divalent inorganic cation.
- It also relates to a method comprising the oral or topical administration of at least an effective amount of at least one microorganism, in particular probiotic microorganism, and/or a fraction thereof and/or a metabolite thereof, in combination with an effective amount of at least one divalent inorganic cation in the form of a salt other than a sulphate.
- the present invention also relates to the use of an effective amount of at least one microorganism, in particular probiotic microorganism, and/or a fraction thereof and/or a metabolite thereof, in combination with an effective amount of at least one divalent inorganic cation, for preparing a composition intended for oral administration and useful for preventing and/or treating sensitive and/or dry skin.
- this combination is formulated in the form of a food supplement, or even a foodstuff.
- the present invention is also directed towards the use, as an agent intended to prevent and/or treat sensitive and/or dry skin, of at least an effective amount of at least one microorganism, in particular probiotic microorganism, and/or a fraction thereof and/or a metabolite thereof, in combination with an effective amount of at least one divalent inorganic cation in the form of a salt other than a sulphate.
- the present invention relates to a cosmetic and/or dermatological composition, that is in particular useful for preventing and/or treating sensitive and/or dry skin, comprising, in a physiologically acceptable carrier, at least an effective amount of at least one microorganism, in particular probiotic microorganism, and/or a fraction thereof and/or a metabolite thereof, in combination with an effective amount of at least two alkaline earth metals in the form of anhydrous or hydrated organic salts, or of chelated complexes.
- the present invention relates to a cosmetic and/or dermatological composition, that is in particular useful for preventing and/or treating sensitive and/or dry skin, comprising, in a physiologically acceptable carrier, at least an effective amount of at least one microorganism, in particular probiotic microorganism, and/or a fraction thereof and/or a metabolite thereof, in combination with an effective amount of at least one alkaline earth metal in the form of a salt chosen from bicarbonates, glycerophosphates, nitrates, acetates, hydroxides, ⁇ -hydroxy acid salts, such as citrates, tartrates, lactates and malates, or salts of fruit acids, amino acid salts, such as aspartates, arginates and fumarates, or fatty acid salts such as palmitates, oleates, caseinates and behenates .
- a salt chosen from bicarbonates, glycerophosphates, nitrates, acetates, hydroxides,
- the term "sensitive skin” covers irritable skin and intolerant skin.
- Intolerant skin is skin that reacts to various factors, such as the application of cosmetic or dermatological products or of soap, through sensations of heating, of tautness, of tingling and/or of redness.
- these signs are associated with erythema and with hyperseborrhoeic or acneic skin, or even skin exhibiting rosacea, with or without sores.
- Irritable skin is skin which reacts through pruritus, i.e. through itching or prickling, to various factors such as the environment, emotions, foods, the wind, rubbing, shaving, hard water with a high calcium concentration, temperature variations or wool.
- these two types of skin may be associated with dryness of the skin with or without sores or with skin that exhibits erythema.
- dryness of the skin is often associated with a decrease in the level of moisturization of the skin, evaluated by corneometry, and with an impairment of the barrier function, measured through the imperceptible loss of water.
- Dry skin essentially manifests itself through a sensation of tautness and/or tension. Said skin is also rough to the touch and appears to be covered with scales. When the skin is slightly dry, these scales are abundant but not very visible to the naked eye. When this condition worsens, there are increasingly fewer of these scales but they are increasingly visible to the naked eye.
- the cause of this dryness of the skin may be of the constitutional or acquired type.
- pathological skin In the case of constitutional dry skin, two categories can be distinguished: pathological skin and non-pathological skin.
- Pathological constitutional dry skin is essentially represented by atopic dermatitis and ichthyoses. It is virtually independent of the outside conditions.
- Atopic dermatitis is described as being associated with a deficiency in metabolism of the lipids of the stratum corneum, and in particular of the ceramides .
- This pathology presents itself in the form of more or less chronic xerosis concerning a large extent of the body, associated with inflammatory and pruriginous exacerbations in plaques .
- Ichthyoses are pathologies characterized by a genetic deficiency that affects the keratinization process at various stages. It manifests itself through considerable desquamation in plaques.
- Non-pathological constitutional dry skin is dry skin for which the severity can depend on the outside factors already mentioned.
- Senile skin characterized by a general decrease in metabolism in the skin with age
- fragile skin very sensitive to outside factors and often accompanied by erythema and rosacea
- common xerosis of probable genetic origin and manifesting itself predominantly on the face, the limbs and the back of the hands enter into this skin category.
- compositions and method according to the invention are thus found to be most particularly effective for preventing and/or treating sensitive and/or dry skin, and more particularly skin referred to as reactive, irritable and/or intolerant, acquired dry skin and/or constitutional dry skin.
- microorganisms that are suitable for the invention are microorganisms that can be administered without risks to animals or humans.
- At least one ⁇ probiotic-type" microorganism is used.
- probiotic microorganism is intended to mean a living microorganism that, when it is consumed in an appropriate amount, has a positive effect on the health of its host "joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotic in Food Including Powder Milk with Live Lactic Acid Bacteria, 6 October 2001", and which can in particular improve the intestinal microbial balance.
- the term "metabolite” denotes any substance that is derived from the metabolism of the microorganisms considered according to the invention and that is also effective for treating sensitive skin.
- fraction denotes more particularly a fragment of said microorganism that is effective for treating dry skin by analogy with said whole microorganism.
- microorganisms that are suitable for the invention can be chosen in particular from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces r Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium, bacteria of the genus Bifidobacterium, Bacteroides, Fusobacterium, Melissococcus, Propionibacterium, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus r Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus and Lactobacillus and mixtures thereof.
- ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces r Torulaspora, Schizosaccharomyces pombe, Debaromyces
- probiotic microorganisms the following genus of bacteria and of straim are generally used:
- Lactobacillus species acidophilus (LCl, NCFB 1748) ; amylovorus, casei (Shirota) , rhamnosus (strain GG) , brevis, crispatus, delbrueckii (subsp bulgaricus, lactis) ) , fermentum, helveticus, gallinarum, gasseri, johnsonii, paracasei, plantarum, reuteri, rhamnosus, salivarius .
- Lactobacillus species acidophilus (LCl, NCFB 1748) ; amylovorus, casei (Shirota) , rhamnosus (strain GG) , brevis, crispatus, delbrueckii (subsp bulgaricus, lactis) ) , fermentum, helveticus, gallinarum, gasseri, johnsonii, paracasei, plantarum, reuteri, rhamnosus,
- Cocci Enterococcus (faecalis, faecium) , Lactococcus lactis (subspp lactis or cremoris) , Leuconstoc mesenteroides subsp dextranlcum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. Thermophilus. - The Bifidobacterium species like Bifidobacterium adolescentis, animalis, bifidum, breve, lactis, longum, infantis.
- the strain Saccharomyces cerevisiae and - The bacteries like Bacillus (cereus var toyo or subtilis) , Bacillus coagulans, B ⁇ licheniformis, Escherichia coli strain nissle, Propionlbacterium freudenreichii.
- probiotic microorganisms are Bifidobacterium bifidum f Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei subsp. Casei, Lactobacillus casei Shirota, Lactobacillus paracasei, Lactobacillus curvatus, Lactobacillus delbruckii subsp.
- Lactis Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus (Lactobacillus GG) , Lactobacillus sake, Lactococcus lactis, Streptococcus thermophilus, Staphylococcus carnosus and Staphylococcus xylosus, and mixtures thereof.
- microorganisms may be formulated in powdered form, i.e. in a dry form, or in the form of suspensions or solutions.
- these microorganisms may be formulated within the compositions according to the invention in an encapsulated form so as to significantly improve their survival time.
- the presence of a capsule can in particular delay or prevent degradation of the microorganism in the gastrointestinal tract.
- the microorganisms are probiotic microorganisms derived from the group of lactic acid bacteria, such as in particular Lactobacillus and/or Bifidobacterium.
- lactic acid bacteria such as in particular Lactobacillus and/or Bifidobacterium.
- Lactobacillus johnsonii Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus easel or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis f Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum, and mixtures thereof.
- the most particularly suitable species are Lactobacillus johnsonii, Lactobacillus paracasei, Bifidobacterium adolescentis, Bifidobacterium longum, and Bifidobacterium lactis NCC 2818 [also entitled (Bb 12) (ATCC27536) ] respectively deposited according to the Treaty of Budapest with the Pasteur Institute (28 rue du Dondel Roux, F-75024 Paris cedex 15) on 30/06/92, 12/01/99, 15/04/99, 15/04/99 and 07/06/2005 under the following designations: CNCM 1-1225, CNCM 1-2116, CNCM 1-2168, and CNCM 1-2170 and CNCM 1-3446, and the genus Bifidobacterium longum (BB536) .
- the Bifidobacterium lactis (CNCM 1-3446) strain can be obtained from Hansen (Chr. Hansen A/S, 10-12 Boege AlIe, P.O. Box 407, DK-2970 Hoersholm, Denmark) .
- the composition comprises at least two microorganisms, in particular probiotic microorganisms, and/or metabolites and/or fractions, that are different.
- microorganisms can differ in terms of their nature, for example bacterium and fungus, or else in terms of family, their genus or their species, or only in terms of their strain.
- composition according to the invention may thus comprise at least one microorganism chosen from those mentioned above and a second microorganism that may or may not also be chosen from these microorganisms.
- the composition contains at least one Lactobacillus sp microorganism and at least one Bifidobacterium sp microorganism, in particular in equivalent amounts, and more particularly in a proportion of 10 10 cfu respectively.
- microorganisms and/or their fractions and/or metabolites can be formulated in an appropriate carrier in an amount of at least 10 3 cfu/g, in particular at doses ranging from 10 5 to 10 15 cfu/g, and more particularly from 10 7 to 10 12 cfu/g of carrier.
- compositions according to the invention can comprise, for the live microorganisms, from 10 3 to 10 15 cfu/g, in particular from 10 5 to 10 15 cfu/g, and more particularly from 10 7 to 10 12 cfu/g of microorganisms per gram of carrier, or at equivalent calculated doses for inactive or dead microorganisms or for microorganism fractions or for produced metabolites .
- compositions for topical application according to the invention generally comprise from 10 3 to 10 12 cfu/g, in particular form 10 5 to 10 10 cfu/g, and more particularly from 10 7 to 10 9 cfu/g of microorganisms, in particular probiotic microorganisms.
- the metabolite contents in the compositions correspond substantially to the contents that can be produced by 10 3 to 10 15 cfu, in particular 10 5 to 10 15 cfu, and more particularly 10 7 to 10 12 cfu of live microorganisms per gram of carrier.
- the concentration of microorganism(s) in particular probiotic microorganism(s)
- the concentration of microorganism(s) can be adjusted so as to correspond to doses (expressed as microorganism equivalent) ranging from 5 X 10 5 to 10 13 cfu/d, and in particular from 10 8 to 10 u cfu/d.
- microorganism(s) can be included in the composition according to the invention in a live, semi-active or inactivated, or dead form.
- microorganism(s) , metabolite (s) or fraction (s) can also be introduced in the form of a lyophilized powder or of a culture supernatant and/or, where appropriate, in a concentrated form.
- topical compositions it may be advantageous to use these microorganisms in inactivated, or even dead, form.
- one or more divalent inorganic cation (s) may be used.
- At least two, or even three, different divalent inorganic cations are used.
- the divalent inorganic cations can be used in various forms.
- the divalent inorganic cation can thus be in the form of an anhydrous or hydrated inorganic or organic salt, or of a chelated complex.
- the salts may, for example, be carbonates, bicarbonates, sulphates, glycerophosphates, chlorides, nitrates, acetates, hydroxides, oxides, ⁇ -hydroxy acid salts (citrates, tartrates, lactates, malates) or salts of fruit acids, or else amino acid salts (aspartate, arginate, fumarate) or fatty acid salts (palmitate, oleate, caseinate, behenate) .
- the divalent inorganic cation is chosen from manganese, copper and/or zinc.
- the divalent inorganic cation is an alkaline earth metal.
- alkaline earth metals that can be used in the invention, mention may be made of barium, calcium, magnesium, strontium and/or beryllium.
- the divalent inorganic cation and in particular alkaline earth metal, is used, in the present invention, in the form of a salt.
- the salt may be chosen from calcium nitrate, strontium nitrate, magnesium gluconate, calcium lactate, strontium gluconate, magnesium lactate, calcium chloride, strontium chloride, magnesium chloride, calcium carbonate, strontium sulphate, magnesium sulphate, calcium glycerophosphate, calcium citrate, magnesium citrate, strontium acetate and magnesium acetate, and mixtures thereof.
- the methods used and the compositions according to the invention use at least two divalent inorganic cations, and in particular two alkaline earth metals, that are in particular different, in the form of organic salts.
- the divalent inorganic cation can also be used in the form of a chelated complex, in particular chelated with crystalline or ionized proteins.
- the divalent inorganic cation may also be in a specific form that is stored by a microorganism, for example of the yeast type, like selenium.
- the cations can be introduced as they are into the compositions according to the invention, or by means of a compound or mixture of compound(s) known to contain a high concentration of at least one of these cations.
- a compound or mixture of compound(s) known to contain a high concentration of at least one of these cations For example, as source of metal salts, use may be made of an extract of plants or yeast rich in cations. Similarly, calcium may, for example, be introduced via a milk extract.
- the divalent inorganic cation content used in the compositions according to the invention depends, of course, on the form of the cation under consideration, and can be determined by means of simple routine experiments. These daily doses can in particular range from 100 ⁇ g to 5 ⁇ g, more particularly from 1 mg to 2 g, or even from 10 mg to 1.3 g.
- the divalent inorganic cation concentration can be adjusted so as to correspond to doses ranging from 1 to 3000 mg/day, and in particular from 10 to 2000 mg/day.
- compositions and methods in accordance with the invention By way of illustration of the compositions and methods in accordance with the invention, mention may in particular be made of those that combine at least one magnesium and/or calcium salt, especially organic salt, and in particular chosen from magnesium gluconate, lactate and/or citrate and/or calcium gluconate, lactate and/or citrate and/or strontium nitrate, with at least one lactic acid bacterium, especially chosen from Lactobacillus sp r and more particularly Bifidobacterium lactis "CNCM 1-3446".
- compositions can be administered topically or orally.
- compositions according to the invention may be in any of the pharmaceutical forms normally used, according to the route for use.
- the carrier may be of diverse nature according to the type of composition under consideration.
- Food or pharmaceutical carriers that are especially suitable include milk, yogurt, cheese, fermented milks, milk-based fermented products, ice creams, fermented cereal-based products, milk-based powders, formulas for children and infants, foods for animals, in particular pets, tablets or lozenges, liquid bacterial suspensions, oral supplements in dry form and oral supplements in liquid form.
- the composition according to the invention may be a food composition for human consumption. It may in particular be complete nutritional foods, drinks, mineral waters, soups, dietetic supplements and replacement foods, nutritional bars, confectionery, milk-based or fermented milk-based products, yogurts, milk-based powders, enteral nutrition products, compositions for children and/or infants, cereal-based products or fermented cereal-based products, ice creams, chocolate, coffee, "culinary" products such as mayonnaise, tomato puree or salad dressings.
- the composition according to the invention may also be intended for animals.
- the cosmetic products may be aqueous, aqueous-alcoholic or oily solutions, dispersions of the solution type or dispersions of the lotion or serum type, emulsions having a liquid or semi-liquid consistency of the milk type, suspensions or emulsions of the cream, aqueous gel or anhydrous gel type, microemulsions, microcapsules, microparticles, or vesicular dispersions of ionic and/or non- ionic type.
- oral compositions and in particular of food supplements are possible. They are formulated by means of the usual methods for producing sugar- coated tablets, gelatine capsules, gels, emulsions, tablets, capsules or solutions.
- the active agent (s) according to the invention can be incorporated into any other forms of food supplements or of enriched foods, for example food bars, or compacted or non-compacted powders.
- the powders can be diluted with water, in a fizzy drink, dairy products or soya-derived products, or can be incorporated into food bars.
- the active agents according to the invention can be formulated with the usual excipients and constituents for such oral compositions or food supplements, i.e. in particular fatty and/or aqueous constituents, humectifying agents, thickeners, preserving agents, texturing, flavouring and/or coating agents, antioxidants, preserving agents and dyes that are usual in the food domain.
- excipients and constituents for such oral compositions or food supplements i.e. in particular fatty and/or aqueous constituents, humectifying agents, thickeners, preserving agents, texturing, flavouring and/or coating agents, antioxidants, preserving agents and dyes that are usual in the food domain.
- oral compositions according to the invention can contain several other active agents.
- vitamins B3, B5, B6, B8, C, E or PP examples of active agents that can be used, mention may be made of vitamins B3, B5, B6, B8, C, E or PP, carotenoids, curcuminoids and niacin.
- an antioxidant complex comprising vitamins C and E, and at least one carotenoid, in particular a carotenoid chosen from ⁇ -carotene, lycopene, astaxanthine, zeaxanthine and lutein, flavonoids such as catechins, hesperidin, proanthocyanidins and anthocyanins.
- a carotenoid chosen from ⁇ -carotene, lycopene, astaxanthine, zeaxanthine and lutein, flavonoids such as catechins, hesperidin, proanthocyanidins and anthocyanins.
- the composition advantageously comprises at least one prebiotic or a mixture of prebiotics.
- these prebiotics can be chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, gums, of the acacia type for example, or a mixture thereof.
- the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may- comprise a mixture of fructooligosaccharide and of inulin.
- the cosmetic and/or dermatological compositions more particularly relating to a topical application can in particular be in the form of aqueous, aqueous-alcoholic or oily solutions, of dispersions of the solution type or dispersions of the lotion or serum type, of emulsions that have a liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice versa (W/0) , or of suspensions or emulsions that have a soft, semi-solid or solid consistency of the cream, aqueous gel or anhydrous gel type, or else of microemulsions, of microcapsules, of microparticles, or of vesicular dispersions of ionic and/or non-ionic type.
- compositions are prepared according to the usual methods.
- compositions can in particular constitute cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for the major anatomical folds or for the body (for example day creams, night creams, makeup- removing creams, foundation creams, sun creams) , makeup products such as fluid foundations, makeup-removing milks, protective or care milks for the body, aftersun milks, skincare lotions, gels or foams, such as cleansing or disinfecting lotions, sun lotions, artificial tanning lotions, bath compositions, deodorant compositions containing a bactericidal agent, aftershave gels or lotions, depilatory creams, or compositions for insect bites.
- cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for the major anatomical folds or for the body (for example day creams, night creams, makeup- removing creams, foundation creams, sun creams)
- makeup products such as fluid foundations, makeup-removing milks, protective or care milks for the body
- compositions according to the invention may also consist of solid preparations constituting soaps or cleansing cakes.
- They may also be used for the hair, in the form of aqueous, alcoholic or aqueous-alcoholic solutions, or in the form of creams, gels, emulsions or mousses, or else in the form of aerosol compositions also containing a pressurized propellant.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight, relative to the total weight of the composition.
- the oils, the emulsifiers and the coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetics and/or dermatological field.
- the emulsifier and the coemulsifier may be present, in the composition, in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight, relative to the total weight of the composition.
- the fatty phase can represent more than 90% of the total weight of the composition.
- the cosmetic and/or dermatological composition of the invention can also contain adjuvants that are normal in the cosmetic, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, bactericides, odour absorbers and dyestuffs.
- adjuvants that are normal in the cosmetic, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, bactericides, odour absorbers and dyestuffs.
- the amounts of these various adjuvants are those conventionally used in the field under consideration and are, for example, from 0.01 to 20% of the total weight of the composition. Depending on their nature, these adjuvants can be introduced into the fatty phase and/or into the aqueous phase.
- mineral oils such as, for example, hydrogenated polyisobutene and liquid petroleum jelly
- plant oils such as, for example, a liquid fraction of shea butter, sunflower oil and apricot kernel oil
- animal oils such as, for example, perhydrosqualene
- synthetic oils in particular purcellin oil, isopropyl myristate and ethylhexyl palmitate
- fluoro oils such as, for example, perfluoropolyethers.
- Use may also be made of fatty alcohols, and fatty acids such as, for example, stearic acid and such as, for example, waxes, in particular paraffin wax, carnauba wax and beeswax.
- silicone compounds such as silicone oils and, for example, cyclomethicone and dimethicone, and waxes, resins and gums that contain silicone. These compounds may or may not be functionalized.
- emulsifiers that can be used in the invention, mention may, for example, be made of glyceryl stearate, polysorbate 60, the mixture of cetyl stearyl alcohol/oxyethylenated cetyl stearyl alcohol containing 33 mol of ethylene oxide sold under the name Sinnowax AO ® by the company Henkel, the mixture of PEG-6/PEG-32/glycol stearate sold under the name Tefose ® 63 by the company Gattefosse, PPG-3 myristyl ether, silicone emulsifiers such as cetyl dimethicone copolyol and sorbitan monostearate or tristearate, PEG-40 stearate, and oxyethylenated (20 EO) sorbitan monostearate.
- glyceryl stearate polysorbate 60
- hydrophilic gelling agents such as carbomer, acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides and in particular the mixture of polyacrylamide, C13-14-isoparaffin and Laureth-7 sold under the name Sepigel 305 ® by the company Seppic, polysaccharides for instance cellulose derivatives such as hydroxyalkylcelluloses and in particular hydroxyl- propylcellulose and hydroxyethylcellulose, natural gums such as guar, carob and xanthan gums, and clays.
- carboxylic polymers such as carbomer, acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides and in particular the mixture of polyacrylamide, C13-14-isoparaffin and Laureth-7 sold under the name Sepigel 305 ® by the company Seppic
- polysaccharides for instance cellulose derivatives such as hydroxyalkylcelluloses and in particular hydroxyl- propylcellulose and
- lipophilic gelling agents mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminium stearates and hydrophobic silica, or else ethylcellulose and polyethylene.
- hydrophilic active agents use may be made of proteins or protein hydrolysates, amino acids, polyols, in particular C 2 to Cio polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, and bacterial or plant extracts such as those of aloe vera.
- polyols in particular C 2 to Cio polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, and bacterial or plant extracts such as those of aloe vera.
- vitamin A retinol
- vitamin E tocopherol
- the active agents according to the invention can also be combined with active agents intended in particular for preventing and/or treating skin conditions .
- composition of the invention can advantageously contain a spring and/or mineral water, in particular chosen from Vittel water, water from the Vichy basin and Roche Posay water.
- the method of cosmetic treatment of the invention can in particular be carried out by applying the cosmetic and/or dermatological compositions as defined above, according to the normal technique for using these compositions. For example: application of creams, gels, sera, lotions, makeup- removing milks or aftersun compositions to the skin or to dry- hair, application of a hair lotion to wet hair, application of shampoos, or else application of dentifrice to the gums.
- the cosmetic method according to the invention can be carried out by topical administration or by oral administration, daily for example, of the combination according to the invention, which may, for example, be formulated in the form of gelatine capsules, gels, lotions, sugar-coated tablets, emulsions, tablets, capsules or oral ampoules, in an appropriate amount and number, according to their form, so that the active agents are administered at a rate of 5 X 10 5 to 10 13 cfu per day, in particular 10 6 to 10 11 cfu per day, in terms of microorganisms, or at equivalent doses of partially inactivated or dead microorganisms or of microorganism fractions or of metabolites produced.
- the administration is repeated until the divalent inorganic cation is administered at doses of the order of 1 to 3000 mg per day, and in particular of 10 to 2000 mg per day.
- the method according to the invention can comprise a single administration.
- the administration is repeated, for example, 2 to 3 times daily, over a day or more, and generally over a prolonged period of at least 4 weeks, or even 4 to 15 weeks, with, where appropriate, one or more periods of interruption.
- the percentages are percentages by- weight and the ranges of values written as "between ... and " include the upper and lower limits specified.
- the ingredients are mixed, before they are formulated, in the order and under conditions that are readily determined by those skilled in the art.
- compositions for topical administration are provided.
- Example 1 Sensitive skin facial lotion
- Lactobacillus sp. powder 5.00 Magnesium gluconate 3.00 Calcium lactate 2.00 Antioxidant 0.05 Isopropanol 40.00 Preserving agent 0.30 Water qs 100%
- Example 2 Dry and sensitive skin facial care milk
- Strontium nitrate 4 00 Lactobacillus sp. 5 . 00 Hydroxypropylcellulose (Klucel H s sold by the company Hercules) 1 . 00 Vitamin E 2 . 50 Antioxidant 0 . 05 Isopropanol 40 . 00 Preserving agent 0 . 30 Water qs 100%
- Example 4 Dry and sensitive skin facial care milk
- Example 8 capsule
- One to three of these capsules can be taken per day.
- One to three capsules can be taken per day.
- Example 10 formulation of the sugar-coated tablet type
- This type of sugar-coated tablet can be taken 1 to 3 times per day.
- Exam le 11 formulation of the sugar-coated tablet type
- This type of sugar-coated tablet can be taken 1 to 3 times per day.
- compositions one based only on a probiotic microorganism (B) and the other combining with this microorganism two alkaline earth metal salts (C) were tested for their effectiveness with respect to skin dryness and sensitivity, with regard to a placebo composition (A) .
- B probiotic microorganism
- C alkaline earth metal salts
- B X 10 10 cfu Lactobacillus paracasei CNCM 1-2116 + 1 x 10 ⁇ l o u cfu Bifidobacterium lactis (CNCM 1-3446) .
- C I X 10 10 cfu Lactobacillus paracasel CNCM 1-2116 + 1 X 10 10 cfu Bifidobacterium lactis (CNCM 1-3446) + 1 g of calcium citrate + 300 mg of magnesium citrate.
- the treatment consists of the daily and oral administration of a single treatment unit for a period of eight weeks .
- the oral composition in accordance with the invention, of the preceding example was tested in terms of skin sensitivity in the individuals considered for the study of Example 10 (evaluation of skin sensitivity by means of a lactic acid test or stinging test) .
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA06015184A MXPA06015184A (en) | 2004-06-23 | 2005-06-22 | Method and compositions useful for preventing and/or treating sensitive and/or dry skin. |
AU2005257033A AU2005257033B2 (en) | 2004-06-23 | 2005-06-22 | Method and compositions useful for preventing and/or treating sensitive and/or dry skin |
JP2007517626A JP2008503563A (en) | 2004-06-23 | 2005-06-22 | Methods and compositions useful for the prevention and / or treatment of sensitive and / or dry skin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0451317 | 2004-06-23 | ||
FR0451317A FR2872047B1 (en) | 2004-06-23 | 2004-06-23 | COMPOSITION FOR SENSITIVE SKINS COMBINING MINERAL AND PROBIOTIC CATION (S) |
US62303904P | 2004-10-29 | 2004-10-29 | |
US60/623,039 | 2004-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006000992A1 true WO2006000992A1 (en) | 2006-01-05 |
Family
ID=34970610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/052049 WO2006000992A1 (en) | 2004-06-23 | 2005-06-22 | Method and compositions useful for preventing and/or treating sensitive and/or dry skin |
Country Status (6)
Country | Link |
---|---|
US (1) | US7651680B2 (en) |
JP (1) | JP2008503563A (en) |
KR (1) | KR20070070153A (en) |
AU (1) | AU2005257033B2 (en) |
MX (1) | MXPA06015184A (en) |
WO (1) | WO2006000992A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008044945A (en) * | 2006-07-26 | 2008-02-28 | Health Vision:Kk | Probiotics as alternative drug confronting infectious disease |
EP2050434A1 (en) * | 2006-08-10 | 2009-04-22 | House Wellness Foods Corporation | Moisturizing agent |
JP2009108031A (en) * | 2007-09-04 | 2009-05-21 | L'oreal Sa | Method for using bifidobacterium species lysate for treating sensitive skin |
WO2009155689A1 (en) * | 2008-06-24 | 2009-12-30 | Micropharma Limited | Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections |
EP2206493A1 (en) | 2009-01-12 | 2010-07-14 | L'oreal | Cosmetic combination of a microorganism and a phytosphingosine derivative |
EP2233128A1 (en) | 2009-03-25 | 2010-09-29 | Cognis IP Management GmbH | Cosmetic composition |
FR2953408A1 (en) * | 2009-12-08 | 2011-06-10 | Oreal | ACTIVE PROBIOTIC MICROORGANISMS FOR SKIN DYE SKIN |
FR2953407A1 (en) * | 2009-12-08 | 2011-06-10 | Oreal | PROBIOTIC MICROORGANISMS AS ACTIVE AGAINST THE ALTERATIONS OF MICRORELIEF |
ITRM20100004A1 (en) * | 2010-01-12 | 2011-07-13 | Giuliani Spa | PROCEDURE FOR THE PREPARATION OF A BIOMASS INCLUDING PLANTARICINA AND ITS USES IN MEDICAL FIELD. |
US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
WO2013153358A1 (en) | 2012-04-13 | 2013-10-17 | The University Of Manchester | Probiotic bacteria |
US8637093B2 (en) | 2008-04-17 | 2014-01-28 | Barry Callebaut Ag | Composition and uses thereof |
US8765191B2 (en) | 2007-10-08 | 2014-07-01 | Barry Callebaut Ag | Cocoa extracts for use in providing skin benefits |
FR3001633A1 (en) * | 2013-02-04 | 2014-08-08 | Inneov Lab | Cosmetic use of a combination comprising at least a first and a second nutritional agents for inducing weight loss to restore, maintain and promote good esthetic condition of skin and to promote weight loss |
US9176144B2 (en) | 2006-11-17 | 2015-11-03 | L'oreal | Cosmetic use of a protein belonging to the ribonuclease family |
US20160271189A1 (en) * | 2015-03-18 | 2016-09-22 | Whole Biome, Inc. | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
EP3199036A4 (en) * | 2014-09-23 | 2018-05-02 | Korea Institute of Oriental Medicine | Composition, containing tyndallized lactobacillus dead cells as active ingredient, for skin moisturizing or wrinkle improvement |
US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5112069B2 (en) * | 2004-10-04 | 2013-01-09 | ロレアル | Cosmetic and / or dermatological composition for sensitive skin |
US7742581B2 (en) | 2004-11-24 | 2010-06-22 | Value-Added Communications, Inc. | Electronic messaging exchange |
US9282188B2 (en) | 2005-01-28 | 2016-03-08 | Value-Added Communications, Inc. | Voice message exchange |
US9876915B2 (en) | 2005-01-28 | 2018-01-23 | Value-Added Communications, Inc. | Message exchange |
US10953051B2 (en) * | 2005-06-22 | 2021-03-23 | Novozymes A/S | Methods and means for protecting the skin against pathogenic microorganisms |
FR2889057B1 (en) * | 2005-08-01 | 2008-07-18 | Oreal | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF SENSITIVE OR DRY SKINS |
FR2919501B1 (en) * | 2007-08-02 | 2010-12-31 | Oreal | USE OF HESPERIDINE OR ONE OF ITS DERIVATIVES FOR THE PREVENTION AND / OR TREATMENT OF RELEASED SKINS |
BRPI0816214B8 (en) * | 2007-09-04 | 2017-12-26 | Oreal | cosmetic use, cosmetic and / or dermatological composition, and methods for the cosmetic treatment of the skin, for the cosmetic treatment of skin signs of aging and / or photoaging, and for the cosmetic treatment to prevent and / or treat dry keratinous substances. |
US20090074735A1 (en) * | 2007-09-19 | 2009-03-19 | Joshi Ashok V | Topical product containing sacrificial material for neutralizing free radicals |
BRPI0916690B1 (en) * | 2008-07-29 | 2022-04-12 | L'oreal | Use of an effective amount of at least one probiotic microorganism, cosmetic and/or dermatological composition, cosmetic method for treating and/or preventing cosmetic disorders of the scalp in a subject, cosmetic process for preventing and/or treating a dandruff condition of the scalp scalp, cosmetic kit, and, cosmetic use of at least an effective amount of at least a first and a second active cosmetic agent |
FR2945944B1 (en) * | 2009-06-02 | 2011-07-15 | Oreal | COSMETIC PROCESS FOR TREATING FILM STATES COMPRISING THE ADMINISTRATION OF A PROBIOTIC MICROORGANISM AND ANTIPELLICULAR ACTIVE INGREDIENT |
FR2938429B1 (en) * | 2008-11-19 | 2012-05-18 | Oreal | COSMETIC USE OF MICROORGANISM (S) FOR THE TREATMENT OF SKIN LEATHER DISORDERS |
FR2938437B1 (en) * | 2008-11-19 | 2020-03-27 | Société des Produits Nestlé S.A. | COSMETIC USE OF MICROORGANISM FOR THE TREATMENT OF OILY SKIN |
FR2937536B1 (en) * | 2008-10-28 | 2016-07-01 | Oreal | COSMETIC USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF FAT SKIN LEATHER |
FR2937547B1 (en) * | 2008-10-28 | 2012-11-09 | Oreal | USE OF A MICROORGANISM LYSATE FOR THE TREATMENT OF FAT SKINS |
CN102281863B (en) * | 2009-01-16 | 2015-08-19 | 新科蒂斯公司 | Calcium sequestration compositions and be used for the treatment of the pigmentation disorder of skin and the method for disease |
US9621714B2 (en) | 2009-01-27 | 2017-04-11 | Value-Added Communications, Inc. | System and method for electronic notification in institutional communication |
CN102802648A (en) * | 2009-05-11 | 2012-11-28 | 雀巢产品技术援助有限公司 | Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders |
WO2011003062A2 (en) * | 2009-07-03 | 2011-01-06 | James Madison University | Probiotic compositions and processes thereof |
EP3260126A1 (en) * | 2009-10-09 | 2017-12-27 | Prothera, Inc. | Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
EP2509429A1 (en) * | 2009-12-08 | 2012-10-17 | Nestec S.A. | Infant formula with probiotics and milk fat globule membrane components |
FR2959128B1 (en) * | 2010-04-23 | 2012-07-13 | Oreal | COSMETIC USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF BODY ODORS |
KR101757504B1 (en) * | 2010-06-28 | 2017-07-12 | 가부시키가이샤 야쿠르트 혼샤 | Skin properties improving agent for oral administration |
US8664463B2 (en) | 2010-10-06 | 2014-03-04 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Reversible adhesives |
EP2449890A1 (en) * | 2010-11-05 | 2012-05-09 | Nestec S.A. | Powdered cereal compositions comprising non-replicating probiotic microorganisms |
KR101957193B1 (en) * | 2012-04-13 | 2019-04-08 | 주식회사 알엔에이 | Compisitiom for anti-inflammation, skin whitening and anti-aging comprising of supernatant of lactic acid bacteria lysate |
WO2014027864A1 (en) * | 2012-08-16 | 2014-02-20 | 경희대학교 산학협력단 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
US20150093462A1 (en) * | 2013-09-30 | 2015-04-02 | Elc Management Llc | Watery Lotion Skin Care Compositions And Methods |
GB201409541D0 (en) * | 2014-05-29 | 2014-07-16 | Univ Manchester | Probiotic Bacteria |
WO2017173240A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
AU2017240069B2 (en) | 2016-03-31 | 2024-03-07 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
EP3544575A1 (en) | 2016-11-23 | 2019-10-02 | GOJO Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
JP7130220B2 (en) * | 2016-12-28 | 2022-09-05 | 高梨乳業株式会社 | skin moisturizer |
JP6994214B2 (en) * | 2017-05-01 | 2022-02-21 | 日本コルマー株式会社 | Food composition for skin improvement |
US10749827B2 (en) | 2017-05-11 | 2020-08-18 | Global Tel*Link Corporation | System and method for inmate notification and training in a controlled environment facility |
JP6976843B2 (en) * | 2017-12-28 | 2021-12-08 | 日清食品ホールディングス株式会社 | Skin condition improving agent |
AT17326U1 (en) * | 2021-03-29 | 2021-12-15 | Sanubiom Gmbh | A skin care composition in powder form from which a gel is made |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0399909A1 (en) * | 1989-05-23 | 1990-11-28 | Elf Sanofi | Cosmetic composition against skin ageing |
EP0737471A2 (en) * | 1995-04-10 | 1996-10-16 | L'oreal | Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom |
FR2733151A1 (en) * | 1995-04-20 | 1996-10-25 | Seppic Sa | THERAPEUTIC COMPOSITION COMPRISING AN IN VIVO ANTIGEN OR GENERATOR OF A COMPOUND COMPRISING A SEQUENCE OF AMINO ACIDS |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
EP0931543A1 (en) * | 1997-12-19 | 1999-07-28 | MERCK PATENT GmbH | Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria |
WO2000070972A1 (en) * | 1999-05-21 | 2000-11-30 | Probi Ab | New composition |
WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
WO2001017365A1 (en) * | 1999-09-07 | 2001-03-15 | Societe Des Produits Nestle S.A. | Method for improving the skin and coat of pets |
EP1110555A1 (en) * | 1999-12-22 | 2001-06-27 | Societe Des Produits Nestle S.A. | Antiadhesive agent for the pathogen flora of the skin |
EP1236463A1 (en) * | 2001-02-23 | 2002-09-04 | Chemisches Laboratorium Dr. Kurt Richter GmbH | Topical cosmetic composition |
US20030003107A1 (en) * | 1997-04-18 | 2003-01-02 | Sean Farmer | Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof |
WO2003070260A1 (en) * | 2002-02-21 | 2003-08-28 | Societe Des Produits Nestle S.A. | A photoprotective orally administrable composition for skin |
WO2003071883A1 (en) * | 2002-02-28 | 2003-09-04 | Centro Sperimentale Del Latte S.P.A. | Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations |
US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
RU2228184C2 (en) * | 2002-06-28 | 2004-05-10 | Закрытое акционерное общество "Партнер" | Complex preparation |
FR2848448A1 (en) * | 2002-12-13 | 2004-06-18 | Oreal | Use of an extract of decaffeinated coffee beans for stimulating the sebaceous function of skin in the treatment of skin ageing |
WO2004054535A1 (en) * | 2002-12-13 | 2004-07-01 | L'oreal | Use of an extract of decaffeinated coffee beans in the preparation of a composition intended to stimulate the sebaceous function of the skin by oral administration |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3156355A (en) * | 1962-02-02 | 1964-11-10 | Jack A Wood | Condiment packet |
US4506173A (en) | 1982-10-25 | 1985-03-19 | Burroughs Corporation | Low power partitioned PLA |
US5733568A (en) * | 1993-12-03 | 1998-03-31 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5716625A (en) | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
IT1296148B1 (en) * | 1996-11-22 | 1999-06-09 | Renata Maria Anna Ve Cavaliere | USE OF LACTIC BACTERIA TO INCREASE THE LEVEL OF CERAMIDES OF THE SKIN AND MUCOSA, AND SUITABLE DERMATOLOGICAL AND COSMETIC COMPOSITIONS |
JP5108174B2 (en) * | 1998-04-01 | 2012-12-26 | ガネデン バイオテック, インコーポレイテッド | Methods, systems, and compositions for reducing cholesterol using Bacillus coagulans spores |
US6461627B1 (en) * | 1998-10-09 | 2002-10-08 | Kabushiki Kaisha Yakult Honsha | Skin preparations for external use |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
EP1062876A1 (en) | 1999-02-25 | 2000-12-27 | Societe Des Produits Nestle S.A. | Caseinoglycomacropeptides as calcification agent |
ES2215600T3 (en) * | 2000-06-26 | 2004-10-16 | Sitia-Yomo S.P.A. | FOOD PRODUCTS CONTAINING A FERMENTED VEGETABLE MATRIX AND RELEVANT PREPARATION PROCEDURE. |
ES2357419T3 (en) | 2000-10-06 | 2011-04-26 | Nestec S.A. | USE OF PROBIOTIC BACTERIA PRODUCERS OF LACTIC ACID TO PROTECT THE SKIN AGAINST INFLAMMATORY, ALLERGIC OR IMMUNOSUPPRESSIVE REACTIONS CAUSED BY ULTRAVIOLET RADIATION. |
US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
DE20202562U1 (en) | 2002-02-19 | 2002-05-23 | Orthomol Pharmazeutische Vertr | Micronutrient combination product with probiotics and prebiotics |
EP1364586A1 (en) | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
EP1374913A1 (en) | 2002-06-25 | 2004-01-02 | L'oreal | Nontherapeutic process for evaluating cutaneous neurosensitivity, corresponding kit and its use |
FR2851889B1 (en) | 2003-03-06 | 2007-05-04 | Larena Sa | PRODUCT INTENDED FOR THE RESTORATION OF TOLERANCE AGAINST FOOD ANTIGENS AND BACTERIALS, AND DIETETIC OR FOOD COMPOSITION CONTAINING SUCH A PRODUCT |
CN1863463B (en) | 2003-06-23 | 2011-05-04 | 雀巢技术公司 | Nutritional formula for promoting intestine barrier maturation |
ES2531597T3 (en) * | 2004-03-04 | 2015-03-17 | E-L Management Corp. | Skin treatment procedure with Lactobacillus extract |
-
2005
- 2005-06-22 KR KR1020077001453A patent/KR20070070153A/en not_active Application Discontinuation
- 2005-06-22 JP JP2007517626A patent/JP2008503563A/en active Pending
- 2005-06-22 WO PCT/IB2005/052049 patent/WO2006000992A1/en active Application Filing
- 2005-06-22 MX MXPA06015184A patent/MXPA06015184A/en active IP Right Grant
- 2005-06-22 AU AU2005257033A patent/AU2005257033B2/en not_active Ceased
- 2005-06-23 US US11/159,198 patent/US7651680B2/en active Active
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0399909A1 (en) * | 1989-05-23 | 1990-11-28 | Elf Sanofi | Cosmetic composition against skin ageing |
EP0737471A2 (en) * | 1995-04-10 | 1996-10-16 | L'oreal | Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom |
FR2733151A1 (en) * | 1995-04-20 | 1996-10-25 | Seppic Sa | THERAPEUTIC COMPOSITION COMPRISING AN IN VIVO ANTIGEN OR GENERATOR OF A COMPOUND COMPRISING A SEQUENCE OF AMINO ACIDS |
US20030003107A1 (en) * | 1997-04-18 | 2003-01-02 | Sean Farmer | Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
EP0931543A1 (en) * | 1997-12-19 | 1999-07-28 | MERCK PATENT GmbH | Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria |
WO2000070972A1 (en) * | 1999-05-21 | 2000-11-30 | Probi Ab | New composition |
WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
WO2001017365A1 (en) * | 1999-09-07 | 2001-03-15 | Societe Des Produits Nestle S.A. | Method for improving the skin and coat of pets |
EP1110555A1 (en) * | 1999-12-22 | 2001-06-27 | Societe Des Produits Nestle S.A. | Antiadhesive agent for the pathogen flora of the skin |
EP1236463A1 (en) * | 2001-02-23 | 2002-09-04 | Chemisches Laboratorium Dr. Kurt Richter GmbH | Topical cosmetic composition |
WO2003070260A1 (en) * | 2002-02-21 | 2003-08-28 | Societe Des Produits Nestle S.A. | A photoprotective orally administrable composition for skin |
WO2003071883A1 (en) * | 2002-02-28 | 2003-09-04 | Centro Sperimentale Del Latte S.P.A. | Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations |
US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
RU2228184C2 (en) * | 2002-06-28 | 2004-05-10 | Закрытое акционерное общество "Партнер" | Complex preparation |
FR2848448A1 (en) * | 2002-12-13 | 2004-06-18 | Oreal | Use of an extract of decaffeinated coffee beans for stimulating the sebaceous function of skin in the treatment of skin ageing |
WO2004054535A1 (en) * | 2002-12-13 | 2004-07-01 | L'oreal | Use of an extract of decaffeinated coffee beans in the preparation of a composition intended to stimulate the sebaceous function of the skin by oral administration |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 200441, Derwent World Patents Index; Class B04, AN 2004-437798, XP002312603 * |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008044945A (en) * | 2006-07-26 | 2008-02-28 | Health Vision:Kk | Probiotics as alternative drug confronting infectious disease |
EP2050434A1 (en) * | 2006-08-10 | 2009-04-22 | House Wellness Foods Corporation | Moisturizing agent |
EP2050434A4 (en) * | 2006-08-10 | 2009-11-11 | House Wellness Foods Corp | Moisturizing agent |
US8114658B2 (en) | 2006-08-10 | 2012-02-14 | House Wellness Foods Corporation | Method of moisturizing skin |
KR101106077B1 (en) * | 2006-08-10 | 2012-01-18 | 하우스 웰니스 푸드 코퍼레이션 | Moisturizing agent |
US9176144B2 (en) | 2006-11-17 | 2015-11-03 | L'oreal | Cosmetic use of a protein belonging to the ribonuclease family |
JP2009108031A (en) * | 2007-09-04 | 2009-05-21 | L'oreal Sa | Method for using bifidobacterium species lysate for treating sensitive skin |
US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
US10238897B2 (en) | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
US8765191B2 (en) | 2007-10-08 | 2014-07-01 | Barry Callebaut Ag | Cocoa extracts for use in providing skin benefits |
US8637093B2 (en) | 2008-04-17 | 2014-01-28 | Barry Callebaut Ag | Composition and uses thereof |
WO2009155689A1 (en) * | 2008-06-24 | 2009-12-30 | Micropharma Limited | Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections |
EP2206493A1 (en) | 2009-01-12 | 2010-07-14 | L'oreal | Cosmetic combination of a microorganism and a phytosphingosine derivative |
US8709454B2 (en) | 2009-01-12 | 2014-04-29 | L'oreal | Combination of a microorganism and a phytosphingosine derivative, composition, methods of use |
EP3143985B1 (en) | 2009-03-04 | 2019-08-14 | L'oreal | Use of probiotic microorganisms to reduce skin irritation |
US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
US8937100B2 (en) | 2009-03-25 | 2015-01-20 | Cognis Ip Management Gmbh | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative |
WO2010108619A1 (en) | 2009-03-25 | 2010-09-30 | Cognis Ip Management Gmbh | Cosmetic composition containing calcium citrate and n-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing |
EP2233128A1 (en) | 2009-03-25 | 2010-09-29 | Cognis IP Management GmbH | Cosmetic composition |
US8592484B2 (en) | 2009-03-25 | 2013-11-26 | Cognis Ip Management Gmbh | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing |
EP2332520A1 (en) * | 2009-12-08 | 2011-06-15 | L'Oréal | Probiotic microorganisms as an active ingredient for enhancing skin radiance |
FR2953408A1 (en) * | 2009-12-08 | 2011-06-10 | Oreal | ACTIVE PROBIOTIC MICROORGANISMS FOR SKIN DYE SKIN |
FR2953407A1 (en) * | 2009-12-08 | 2011-06-10 | Oreal | PROBIOTIC MICROORGANISMS AS ACTIVE AGAINST THE ALTERATIONS OF MICRORELIEF |
EP2332521A1 (en) * | 2009-12-08 | 2011-06-15 | L'Oréal | Probiotic microorganisms as actives against changes in the skin's microrelief |
WO2011070509A1 (en) * | 2009-12-08 | 2011-06-16 | L'oreal | Probiotic microorganisms as active agents against changes in the skin's microrelief |
WO2011070508A1 (en) * | 2009-12-08 | 2011-06-16 | L'oreal | Probiotic microorganisms as active agents for enhancing the radiance of the skin's complexion |
ITRM20100004A1 (en) * | 2010-01-12 | 2011-07-13 | Giuliani Spa | PROCEDURE FOR THE PREPARATION OF A BIOMASS INCLUDING PLANTARICINA AND ITS USES IN MEDICAL FIELD. |
WO2011086589A1 (en) * | 2010-01-12 | 2011-07-21 | Giuliani S.P.A. | Process for the preparation of a biomass comprising plantaricin and uses thereof in medical field |
CN102844039A (en) * | 2010-01-12 | 2012-12-26 | 吉利亚尼股份公司 | Process for the preparation of a biomass comprising plantaricin and uses thereof in medical field |
US11590176B2 (en) | 2012-02-29 | 2023-02-28 | Johnson & Johnson Consumer Inc. | Compositions of microbiota and methods related thereto |
US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10729732B2 (en) | 2012-02-29 | 2020-08-04 | Ethicon Endo Surgery, Inc. | Compositions of microbiota and methods related thereto |
WO2013153358A1 (en) | 2012-04-13 | 2013-10-17 | The University Of Manchester | Probiotic bacteria |
EP3888628A1 (en) | 2012-04-13 | 2021-10-06 | Skinbiotherapeutics PLC | Cosmetic use of a probiotic bacteria lysate |
FR3001633A1 (en) * | 2013-02-04 | 2014-08-08 | Inneov Lab | Cosmetic use of a combination comprising at least a first and a second nutritional agents for inducing weight loss to restore, maintain and promote good esthetic condition of skin and to promote weight loss |
EP3199036A4 (en) * | 2014-09-23 | 2018-05-02 | Korea Institute of Oriental Medicine | Composition, containing tyndallized lactobacillus dead cells as active ingredient, for skin moisturizing or wrinkle improvement |
US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US20160271189A1 (en) * | 2015-03-18 | 2016-09-22 | Whole Biome, Inc. | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Also Published As
Publication number | Publication date |
---|---|
AU2005257033A1 (en) | 2006-01-05 |
JP2008503563A (en) | 2008-02-07 |
AU2005257033B2 (en) | 2011-05-12 |
US20060008453A1 (en) | 2006-01-12 |
US7651680B2 (en) | 2010-01-26 |
KR20070070153A (en) | 2007-07-03 |
MXPA06015184A (en) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005257033B2 (en) | Method and compositions useful for preventing and/or treating sensitive and/or dry skin | |
AU2005291098B2 (en) | Cosmetic and/or dermatological composition for sensitive skins | |
ZA200700602B (en) | Method and compositions useful for preventing and/or treating sensitive and/or dry skin | |
AU2006274792B2 (en) | Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin | |
CN101090706B (en) | Cosmetic or dermatologic composition against sensitive skin | |
US10238897B2 (en) | Use of a lysate of bifidobacterium species for treating sensitive skin | |
US8951775B2 (en) | Cosmetic use of microorganisms for the treatment of oily skin | |
US20180243590A1 (en) | Cosmetic use of bifidobacterium species lysate for the treatment of dryness | |
EP1642570A1 (en) | Cosmetic or dermatologic composition against dry and/or sensitive skin | |
SG181510A1 (en) | Probiotic microorganisms as active agents against changes in the skin's microrelief | |
EP1731137A1 (en) | Cosmetic or dermatologic composition against dry and/or sensitive skin | |
US9730905B2 (en) | Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections | |
WO2008078050A2 (en) | Use of at least one mono-unsaturated fatty acid for the treatment of fragile skin, mucous or semi-mucous tissues and scalp | |
CA2522717C (en) | Cosmetic and/or dermatological composition for sensitive skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/015184 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005257033 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007517626 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077001453 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/00602 Country of ref document: ZA Ref document number: 200700602 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2005257033 Country of ref document: AU Date of ref document: 20050622 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005257033 Country of ref document: AU |
|
122 | Ep: pct application non-entry in european phase |